Neonatal treatment with 192 IgG-saporin produces long-term forebrain cholinergic deficits and reduces dendritic branching and spine density of neocortical pyramidal neurons.
The role of basal forebrain-derived cholinergic afferents in the development of neocortex was studied in postnatal rats. Newborn rat pups received intraventricular injections of 192 IgG-saporin. Following survival periods ranging from 2 days to 6 months, the brains were processed to document the cholinergic lesion and to examine morphological consequences. Immunocytochemistry for choline acetyltransferase (ChAT) and in situ hybridization for ChAT mRNA demonstrate a loss of approximately 75% of the cholinergic neurons in the medial septum and nucleus of the diagonal band of Broca in the basal forebrain. In situ hybridization for glutamic acid decarboxylase mRNA reveals no loss of basal forebrain GABAergic neurons. Acetylcholinesterase histochemistry demonstrates a marked reduction of the cholinergic axons in neocortex. Cholinergic axons are reduced throughout the cortical layers; this reduction is more marked in medial than in lateral cortical areas. The thickness of neocortex is reduced by approximately 10%. Retrograde labeling of layer V cortico-collicular pyramidal cells reveals a reduction in cell body size and also a reduction in numbers of branches of apical dendrites. Spine densities on apical dendrites are reduced by approximately 20-25% in 192 IgG-saporin-treated cases; no change was detected in number of spines on basal dendrites. These results indicate a developmental or maintenance role for cholinergic afferents to cerebral cortical neurons.
Robertson
R T
RT
Department of Anatomy and Neurobiology, College of Medicine, University of California, Irvine, 92697-1275, USA. rtrobert@uci.edu
Gallardo
K A
KA
Claytor
K J
KJ
Ha
D H
DH
Ku
K H
KH
Yu
B P
BP
Lauterborn
J C
JC
Wiley
R G
RG
Yu
J
J
Gall
C M
CM
Leslie
F M
FM
D000110:Acetylcholinesterase / Q000032:analysis; D000818:Animals; D000831:Animals, Newborn; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D001369:Axons / Q000187:drug effects / Q000201:enzymology; D002452:Cell Count; D048429:Cell Size / Q000187:drug effects; D002795:Choline O-Acetyltransferase / Q000032:analysis; D018678:Cholinergic Agents / Q000494:pharmacology*; D002799:Cholinergic Fibers / Q000187:drug effects / Q000201:enzymology; D003712:Dendrites / Q000187:drug effects*; D000922:Immunotoxins / Q000494:pharmacology*; D009699:N-Glycosyl Hydrolases; D016548:Prosencephalon / Q000166:cytology / Q000187:drug effects; D017966:Pyramidal Cells / Q000187:drug effects / Q000648:ultrastructure*; D051381:Rats; D017207:Rats, Sprague-Dawley; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins; D013788:Thalamus / Q000166:cytology / Q000254:growth & development; D014793:Visual Cortex / Q000166:cytology* / Q000254:growth & development
C085696:192 IgG-saporin; D000911:Antibodies, Monoclonal; D018678:Cholinergic Agents; D000922:Immunotoxins; D054789:Ribosome Inactivating Proteins, Type 1; D002795:Choline O-Acetyltransferase; D000110:Acetylcholinesterase; D009699:N-Glycosyl Hydrolases; D000076985:Saporins